Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9C000: Variant p.Pro1214Arg

NACHT, LRR and PYD domains-containing protein 1
Gene: NLRP1
Feedback?
Variant information Variant position: help 1214 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Proline (P) to Arginine (R) at position 1214 (P1214R, p.Pro1214Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (P) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In AIADK; decreased interaction with DPP9, leading to increased inflammasome activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 1214 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1473 The length of the canonical sequence.
Location on the sequence: help LEKPARVELHHIVLENPSFS P LGVLLKMIHNALRFIPVTSV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         LEKPARVELHHIVLENPSFSPLGVLLKMIHNALRFIPV-TSV

Zebrafish                     LESVELTRFHAKILQ-PMFSPKTVLVKL------GIPVKVH

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1473 NACHT, LRR and PYD domains-containing protein 1
Chain 1213 – 1473 NACHT, LRR and PYD domains-containing protein 1, C-terminus
Domain 1079 – 1364 FIIND
Region 1213 – 1364 UPA
Mutagenesis 1211 – 1211 S -> A. Partial loss of autocatalytic processing and of IL1B release.
Mutagenesis 1212 – 1212 F -> A. Complete loss of autocatalytic processing and of IL1B release.
Mutagenesis 1213 – 1213 S -> A. Complete loss of autocatalytic processing and of IL1B release. Autocatalytic processing cannot be restored by treatment with hydroxylamine. Abolished interaction with DPP9. Loss of activation by dsRNA or positive-strand RNA virus.
Mutagenesis 1213 – 1213 S -> C. Complete loss of autocatalytic processing, which can be restored by treatment with hydroxylamine.
Mutagenesis 1214 – 1214 P -> A. Partial loss of autocatalytic processing (50%) and of IL1B release (50%).



Literature citations
Human DPP9 represses NLRP1 inflammasome and protects against autoinflammatory diseases via both peptidase activity and FIIND domain binding.
Zhong F.L.; Robinson K.; Teo D.E.T.; Tan K.Y.; Lim C.; Harapas C.R.; Yu C.H.; Xie W.H.; Sobota R.M.; Au V.B.; Hopkins R.; D'Osualdo A.; Reed J.C.; Connolly J.E.; Masters S.L.; Reversade B.;
J. Biol. Chem. 293:18864-18878(2018)
Cited for: FUNCTION; ACTIVITY REGULATION; SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANT AIADK ARG-1214; DPP9 sequesters the C terminus of NLRP1 to repress inflammasome activation.
Hollingsworth L.R.; Sharif H.; Griswold A.R.; Fontana P.; Mintseris J.; Dagbay K.B.; Paulo J.A.; Gygi S.P.; Bachovchin D.A.; Wu H.;
Nature 592:778-783(2021)
Cited for: STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS) IN COMPLEX WITH DPP9; FUNCTION; ACTIVITY REGULATION; INTERACTION WITH DPP9; MUTAGENESIS OF 1193-LEU-LEU-1194; SER-1213; HIS-1276; LYS-1277 AND GLU-1322; CHARACTERIZATION OF VARIANT AIADK ARG-1214; A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis).
Grandemange S.; Sanchez E.; Louis-Plence P.; Tran Mau-Them F.; Bessis D.; Coubes C.; Frouin E.; Seyger M.; Girard M.; Puechberty J.; Costes V.; Rodiere M.; Carbasse A.; Jeziorski E.; Portales P.; Sarrabay G.; Mondain M.; Jorgensen C.; Apparailly F.; Hoppenreijs E.; Touitou I.; Genevieve D.;
Ann. Rheum. Dis. 76:1191-1198(2017)
Cited for: INVOLVEMENT IN AIADK; VARIANTS AIADK TRP-726 AND ARG-1214;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.